Drugs /

orelabrutinib

Back to Drugs List

Overview

NCI Definition [1]:
A small molecule inhibitor of Bruton's tyrosine kinase (BTK; Bruton agammaglobulinemia tyrosine kinase) with potential antineoplastic activity. Upon administration, BTK inhibitor ICP-022 binds to and inhibits the activity of BTK. This prevents both the activation of the B-cell antigen receptor (BCR) signaling pathway and BTK-mediated activation of downstream survival pathways, inhibiting the growth of malignant B-cells that overexpress BTK. BTK, a member of the Src-related BTK/Tec family of cytoplasmic tyrosine kinases, is overexpressed or mutated in B-cell malignancies; it plays an important role in the development, activation, signaling, proliferation and survival of B-lymphocytes.

Clinical Trials

View Clinical Trials for orelabrutinib

Orelabrutinib has been investigated in 2 clinical trials, of which 2 are open and 0 are closed. Of the trials investigating orelabrutinib, 2 are phase 1/phase 2 (2 open).

MS4A1 Expression is the most frequent biomarker inclusion criterion for orelabrutinib clinical trials.

B-cell non-hodgkin lymphoma, chronic lymphocytic leukemia, and follicular lymphoma are the most common diseases being investigated in orelabrutinib clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Orelabrutinib
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating orelabrutinib and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
icp-022, btk inhibitor icp-022, icp 022, icp022
Drug Target(s) [2]:
BTK
NCIT ID [1]:
C156173

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.